Poster Session B
Saturday, November 3
6:00-8:00 p.m.

B001 [Advocate Abstract:] Multiple Myeloma in Puerto Rico. Marisel Brignoni, dot4life, Puerto Rico

B002 Improving knowledge and identifying barriers to screening for hepatitis B and hepatocellular carcinoma in trainees. Patricia Jones, University of Miami, Miami, Florida

B003 [Advocate Abstract:] Rebecca Esparza, Ovarian Cancer Research Fund Alliance

B006 Development of a novel therapeutic splice-switching oligonucleotide targeting race-related androgen receptor signaling and aggressive prostate cancer. Bonnie LaCroix, Duke Cancer Institute, Durham, NC

B007 Racial differences in survival among veterans and non-veteran populations with stage I non-small cell lung cancer. Naomi Alpert, Icahn School of Medicine at Mount Sinai, New York, NY

B008 South Carolina’s National Breast and Cervical Cancer Early Detection Program Narrows the Gap in South Carolina Breast Cancer Disparities. Swann Arp Adams, University of South Carolinia, Columbia, SC

B009 A qualitative assessment of challenges to return to work for colorectal cancer survivors: multi-stakeholder perspectives. Matthew Banegas, Kaiser Permanente Center for Health Research, Portland, OR

B010 Association of cancer survivors’ sociodemographic characteristics with survivorship care patterns. Michael Halpern, Temple University, Philadelphia, PA

B011 Changes in prescriptions for breast cancer medications after Medicaid expansion. Michael Halpern, Temple University, Philadelphia, PA

B012 An Investigation of Travel Distances for Breast Cancer Treatment Among a Racially and Socio-Economically Diverse Cohort. Sue Heiney, University of South Carolina, Columbia, SC

B013 Associations between psychosocial distress and physical inactivity and poor health in medically underserved cancer survivors in central Pennsylvania. Scherezade Mama, The Pennsylvania State University, University Park, Pennsylvania
B014 Differences in the impact of marital status on risk of suicide among cancer survivors based on cancer sites. Nosayaba Osazuwa-Peters, Saint Louis University, Saint Louis, MO

B015 Women in survivorship health using Project ECHO: Creating a model for navigated care transitions. Andrew Sussman, University of New Mexico, Albuquerque, New Mexico

B016 PREDICTORS OF NON-ADHERENCE TO ADJUVANT HORMONAL THERAPY AMONG BREAST CANCER PATIENTS. Samantha Truman, University of South Carolina, Columbia, SC

B017 Role of CYP3A5 in modulating androgen receptor signaling and its relevance in African American prostate cancer patients. Priyatham Gorjala, Roseman University of Health Sciences, Las Vegas, NV

B018 Exploring racial disparities in breast reconstruction after mastectomy at a NCI-Designated Cancer Center. Shahnjayla Connors, University of Houston-Downtown, Houston, TX

B019 Using Big Data to investigate disparities in cervix cancer survival: Racial and ethnic minorities and those with income and insurance disparities have worse overall survival from cervix cancer. Christine Fisher, University of Colorado, Aurora, CO

B020 Anti-proliferative efficacy of different targeted drugs on breast cancer cell lines of distinct subtypes. Meron Yohannes Nigussie, Addis Ababa University, Addis Ababa, Ethiopia

B021 Canine CAR T-cells therapy for mammary carcinoma in dogs. Xavier Ramos-Cardona, Purdue University, West Lafayette, Indiana

B022 Diversity of enrollment in prostate cancer clinical trials: Current status and future directions. Emily Rencsok, Harvard Medical School, Boston, MA

B023 Racial-ethnic disparities in the receipt of initial, cure-intended treatment for localized prostate cancer, SEER Medicare, 2004–2013. Thomas B Richards, CDC, Atlanta, GA

B024; PR07 Racial Differences in Financial Toxicity among Metastatic Breast Cancer Patients. Cleo Samuel, UNC Gillings School of Global Public Health, Chapel Hill, NC

B025 Examining the role of perceived respect on racial disparities in cancer-related pain.. Cleo Samuel, UNC Gillings School of Global Public Health, Chapel Hill, NC

B026 Racial and Educational Differences in Symptom Burden and Supportive Care among Breast Cancer Patients Undergoing Chemotherapy. Cleo Samuel, UNC Gillings School of Global Public Health, Chapel Hill, NC

B027 Disparities in care by race and ethnicity for rectosigmoid cancer patients. Kasim MirzaC, Los Angeles, CA, Los Angeles

B028 Examining cost variation across palliative care delivery models for cancer patients: A systematic review. Samantha Joseph, Florida Agricultural & Mechanical University, Tallahassee, FL
B029 Chinese American Pain Experience (CAPE) project: A mixed methods study to understand cancer-related pain management in Chinese American patients in New York City. Simona Kwon, NYU School of Medicine, NYC, NY

B030 Comparative analysis of cell viability of two Triple Negative breast cancer cell lines using 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4 hydroxy-tamoxifen. Anastasia Robinson, Howard University, Washington, D.C.

B031 Mediating Factors for Perceived Impact of Prostate Cancer Survivors. Antoine B. Richards, Clark Atlanta University, Atlanta, GA

B032 Which forms of financial hardship predict financial distress among African American and white cancer survivors? Theresa Hastert, Wayne State University/Karmanos Cancer Institute, Detroit, MI

B033 Breast cancer and other cause of death among adult women in rural Ethiopia: Presentation and duration of suffering using the direct sisterhood method. Wondimu Ayele Manamo, School of Public Health Addis Ababa University, Ethiopia and Institute of Medical Epidemiology, Biostatistics and Informatics Martin-Luther University, Halle(Saale), Germany, Addis Ababa, Akaki Kality, Ethiopia

B034 Assessment of the prevalence and diagnosis of breast abnormalities among adult women in rural Ethiopia. Wondimu Ayele Manamo, School of Public Health Addis Ababa University, Ethiopia and and Institute of Medical Epidemiology, Biostatistics and Informatics Martin-Luther University, Halle(Saale), Germany, Addis Ababa, Addis Ababa, Ethiopia

B035 Health-related quality of life among Detroit lung cancer survivors: Findings from the Detroit ROCS studies. Julia Mantey, Wayne State University and Karmanos Cancer Institute, Detroit, MI

B036 Self-perceived health status, poor physical and mental health days among cancer survivors with different socioeconomic status. Sarah O’Connor, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas

B037 The role of HIV status in health-related quality of life in gay and bisexual prostate cancer survivors: Findings from the Restore study. Elizabeth Polter, University of Minnesota, Minneapolis, MN

B038 The effects of coaching and action planning on patient activation and quality of life in vulnerable cancer patients. Shelby Roberts, SSR Advisors, Atlanta, GA

B039 The impact of social and built environments on quality of life among cancer survivors. Salma Shariff-Marco, University of California, San Francisco, San Francisco, CA

B040 The impact of racial/ethnic discrimination and residential segregation on cancer survivorship. Salma Shariff-Marco, University of California, San Francisco, San Francisco, CA

B042 Loss of nuclear alpha catenin contributes to chemoresistance and aggressive disease in African American triple negative breast cancer patients. Rania Bassiouni, University of Southern California, Los Angeles, CA
B043 Racial and sex variability in pediatric ALL survival is explained by immunogenic subtypes. Phatsimo Masire, Thomas Jefferson University, Philadelphia, PA

B044 PVT1 exons 4A and 4B overexpressed in prostate cancer in black males regulate prostate epithelial cell proliferation and migration. Gargi Pal, CUNY Hunter College, New York, NY

B045 Exosomal microRNAs are associated with prostate cancer aggressiveness in African American patients. Hamdy Ali, Department of Pharmaceutical Sciences, Rangel College of Pharmacy, Texas A&M Health Sciences Center, College Station, Texas

B046 SAHA and EGCG reduce breast cancer migration, possibly through modulation of cIAP2. Kayla Lewis, University of Alabama at Birmingham, Birmingham, Alabama

B047 Advanced glycation end products promote prostate tumor growth and are a potential biological consequence of lifestyle factors contributing to cancer disparity. David Turner, MUSC, Charleston, SC

B048 Understanding the molecular basis of ER (+) breast cancer among racial groups: metabolic and proteomic profiling. Ashlie Santaliz-Casiano, University of Illinois, Urbana-Champaign, IL

B049 PR08 Higher expression of SATB2 gene in hepatocellular carcinoma of African American patients determines aggressiveness phenotypes than those in Caucasian Americans. Rakesh Srivastava, LSUHSC-NO, New Orleans, LA

B050 Identification of differentially expressed and spliced genes between breast, colon, lung, and prostate cancer from African American and white patients. Muthana Al Abo, Duke Cancer Institute, Durham, NC, U.S

B051 IFNL4-deltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer. Stefan Ambs, NCI/NIH, Bethesda, Maryland

B052 Identification of differentially expressed micro-RNAs in African American women with Quadruple Negative Breast Cancer. Anusha Angajala, Tuskegee University, Tuskegee, AL

B053 Expression of alternative mRNA splicing variant MBD2_v2 promotes triple negative breast cancer tumor initiation and is associated with body mass index. Aliccia Bollig-Fischer, Karmanos Cancer Institute, Wayne State University, Detroit, MI

B054 Analysis of a cancer gene expression and next generation sequencing dataset representing hispanic predominant South Florida population. Zuanel Diaz, Miami Cancer Institute, Baptist Health South Florida, Miami, Florida

B055 Characterization of immune cell subsets from tissue expression profiles in African American triple-negative breast cancer patients. Lee Gibbs, Keck School of Medicine of University of Southern California, Los Angeles, California
B056 Tumor-associated ACKR1/DARC is correlated with a unique signature of pro-inflammatory chemokines and TILs in African-American women with breast cancer. Brittany Jenkins, University of Georgia, Athens, GA

B057 Racial disparity research in ovarian cancer: evaluating race definition in differential gene expression. Luciana Madeira da Silva, University of South Alabama, Mobile, AL

B058 In silico and in vivo analysis of the Duffy Antigen Receptor for Chemokines (DARC) in the breast tumor microenvironment. Rachel Martini, University of Georgia, Athens, GA

B059 African American pancreatic cancer microRNAs profile to identify links to drug resistance and tumor progression. Maria Munoz-Sagastibelza, SUNY Downstate Medical Center, Brooklyn, NY

B060 Health Disparities and the Molecular Genomics of Colorectal Cancer by Ancestry: The Translational Impact on Colorectal Cancer Screening, Surveillance, and Treatment. Parvathi Myer, Albert Einstein College of Medicine, Bronx, NY

B061 Mechanistic and functional interrogation of novel ancestry-related alternatively spliced androgen receptor signal genes in prostate cancer. Rob Onyenwoke, North Carolina Central University, Durham, North Carolina

B062 Genetic driving factors of aggressive Ethiopian breast cancer. Shelly Peyton, UMass Amherst, Amherst, MA


B064 Investigation of the breast microbiome and mucosal immune system in African American and non-Hispanic White women with and without breast cancer: A pilot study. Athena Starlard-Davenport, University of Tennessee Health Science Center, Memphis, TN

B065 Polo-like kinase 1 (PLK1) and aurora kinase B (AURKB) collude with survivin to augment tumor cell proliferation in African-American TNBC: Implications for racial disparity. Chakravarthy Garlapati, Georgia State University, Atlanta, Georgia

B066 SCUBE3 Inhibition Improves Doxorubicin Response in Breast Cancer. Benjamin Onyeagucha, UT Health Science Center at San Antonio, San Antonio, TX

B067 L-arginine in the regulation of NOS2 expression to overcome renal cell carcinoma tumor growth. Charity Sylvester, Louisiana State University Health Science Center - New Orleans, New Orleans, Louisiana

B068; PR09 MicroRNA-1205 regulation of FRYL and aggressive prostate cancer in men of African ancestry. Michelle Naidoo, Hunter College of the City University of New York, New York, NY

B069 Ecological model links Proto-oncogene to high susceptibility of Blacks to TRPV6-expressing metastatic cancers. Constance Hilliard, University of North Texas, Denton, TX
B070 Loss of cytoskeletal protein palladin desensitizes pancreatic cancer associated fibroblast to TGFβ1-dependent desmoplastic induction. Jennifer Alexander, Drexel University College of Medicine, Philadelphia, PA

B071 Genomic differences between non-small cell lung cancer (NSCLC) in African American and white patients. Jennifer Freedman, Duke Cancer Institute, Durham, NC

B072 Cadmium elicits a differential cytotoxic response in triple negative breast cancer cells. Sherette Godfrey, North Carolina A&T State University, Greensboro, North Carolina

B073 Estimating genetic ancestry of commonly used cancer cell lines. Stanley Hooker, City of Hope, Duarte, CA

B074 Development of genetic assays for the surveillance of HPV 90 in New Orleans. LaKia Williams, Tulane University, New Orleans, Louisiana

B075 Effect modifiers of surgery and adjuvant hormone treatment delays among patients diagnosed with breast cancer in South Carolina. Oluwole Babatunde, University of South Carolina, Columbia, South Carolina

B076 Did the Affordable Care Act Improve Insurance Coverage and Stage at Diagnosis among Nonelderly Underserved Breast Cancer Patients? Alexandrina Balanean, Department of Public Health Sciences, Loyola University Chicago, Maywood, IL

B077; PR10 Fewer rural cancer patients treated with antineoplastic agents. Cathy Bradley, University of Colorado, Aurora, CO

B078 [Advocate Abstract:] Susie Brain, UCSF Athena Breast Health Network

B079 The Affordable Care Act and cancer stage in an underserved population. Yan Lu, JPS Health Network, Fort Worth, TX

B080 Insurance status and delayed adjuvant chemotherapy among women with breast cancer at an urban public hospital. Yan Lu, JPS Center for Outcomes Research, Fort Worth, TX

B081 How patient cost sharing of tyrosine kinase inhibitors affects initiation, adherence, and outcomes in patients with newly diagnosed chronic myeloid leukemia: A retrospective claims-based study. Hsiao Ling Phuar, The University of Texas Health Science Center at Houston School of Public Health, Houston, Texas

B082 Precision medicine guided by Next Generation Sequencing: Slow recognition of emerging technologies leads to crucial coverage gaps in health insurance. Phoebe Rollyson, FWCC, Shreveport, LA

B083 Patterns of HIV testing among New Jersey Medicaid enrollees diagnosed with invasive cervical cancer. Jennifer McGee-Avila, Rutgers, the State University of New Jersey, Newark, NJ

B084 Factors associated with longer time to surgical treatment in melanoma. Marissa Baranowski, Department of Dermatology, Emory University School of Medicine; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia
B085 Disparities and factors associated with 30-day mortality following surgical treatment for squamous cell head and neck cancer with or without adjuvant therapy. Aleksandr Bukatko, Saint Louis University, Saint Louis, Missouri

B086 Planning for the Unexpected: Strategies for Maintaining a Robust Clinical Trial Program. Lemuel Melecio, UPR MSC, San Juan, PR

B087 Disparities and trends in genetic testing and erlotinib treatment among metastatic non-small cell lung cancer patients. Lauren Palazzo, Massachusetts General Hospital Institute for Technology Assessment, Boston, MA

B088 Health insurance status, stage at presentation and survival among female patients with head and neck cancer. Neelima Panth, Duke University School of Medicine, Durham, NC

B089 [Advocate Abstract:] Sheila McGlown, St Louis Breast Cancer Foundation, ,

B090 Exploring the Roles of CHWs in Improving Uptake of Family Health History Assessment among Patients and Providers: Implications for Cancer Risk Reduction and Prevention among Minority Populations. Caitlin Allen, Emory University, Atlanta, Georgia

B091 Across border: Towards increasing Pap testing and HPV knowledge and acceptability among minority populations. Kimlin Ashing, City of Hope Comprehensive Cancer Center, Duarte, CA

B092 Promoting HPV vaccination among adolescent girls in Ghana, West Africa: a case study. Joycelyn Cudjoe, Johns Hopkins School of Nursing, Baltimore, MD

B093 Cervical cancer screening among Blacks: A comparative analysis from the 2010-2014 National Health Interview Surveys. Joycelyn Cudjoe, Johns Hopkins School of Nursing, Baltimore, Maryland

B094 Impact of a multi-theory-driven community-based intervention to increase mammographic screening in a Midwest American Indian tribe. Wesely Petersen, Mayo Clinic, Rochester, MN

B095 Eat, Move, Live: An Intervention Strategy for the Reduction of Cancer and Chronic Diseases Tailored to the Latina Population. Cristal Resto, City of Hope, Duarte, CA

B096 Responding to stakeholder needs for cancer screening and prevention: using formative evaluation to tailor outreach and navigation programming in Connecticut. Sakinah Suttiratana, Yale School of Medicine, Yale Cancer Center, New Haven, CT

B097 Knowledge of cervical cancer risk factors and screening among Sub Saharan African Immigrant Women. Adebola Adegboyega, University of Kentucky, Lexington, KY

B098 Individual and Contextual Factors Associated with Prostate Cancer Stage at Diagnosis: A Multi-State Study. Georges Adunlin, Samford University, Birmingham, Alabama

B099; PR12 CRC screening in rural community clinics using the Fecal Immunochemical Test (FIT): Issues with repeat screening. Connie Arnold, Feist-Weiller Cancer Center and LSU Health Sciences Center, Shreveport, Louisiana
B100 Reported Barriers to Colorectal Cancer Screening in Appalachian Kentucky. Adaeze Aroh, University of Kentucky, Lexington, Kentucky of America

B101 Assessment and resolution of breast and cervical cancer screening barriers for underserved women in Louisiana. Janet Brown, LSUHSC School of Public Health, New Orleans, LA

B102 Factors Contributing to Precancerous Polyp Detection in Initial Screening Colonoscopies. Yakira David, Stony Brook University, Stony Brook, NY

B103 Community-based uptake of self-sampling for HPV DNA-based testing for cervical cancer screening in Ethiopia: Preliminary findings of a cluster randomized trial. Muluken Gizaw, Addis Ababa University, School of Public Health, Department of Preventive medicine, Addis Ababa, Ethiopia

B104 [Advocate Abstract:] Evaluating the Impact of Strategic Partnerships. Beaulah Brent, Sisters Working It Out, NFP, IL

B105 Providing Colorectal Cancer Screening Interventions at Federally Qualified Health Centers (FQHCs): Addressing the Issues of Language, Culture and Health Literacy Through Culturally Tailored Education and Navigation. Kathryn Glaser, Roswell Park Comprehensive Cancer Center, Buffalo, NY

B106 Cervical cancer screening modalities by state, 2016. Ann Goding Sasuer, American Cancer Society, Atlanta, GA

B107 Cervical cancer screening behaviors and perceptions of medical mistrust among rural Black and White women. Marla B. Hall, PhD, MCHES, East Carolina University, Greenville, North Carolina

B108 Using patient navigation to inform determinants of breast cancer disparities among under-resourced women in Chicago. Vida Henderson, University of Illinois Cancer Center, Chicago, IL

B109 Architecture of increased breast cancer risk. Karen Herold, City of Hope, Duarte, CA

B110 Reducing Cancer Disparities through Identification of Linkages to Care Partners within GMaP Region 1 North. Julia Houston, University of South Carolin, Columbia, SC

B111 Previous mammography experience as a predictor of mammography adherence among Hispanic/Latinas living in the Northeast. Beth Jones, Yale School of Medicine, Yale Cancer Center, New Haven, CT

B112 Influence of cholesterol screening on breast cancer detection & survival in the Breast Cancer Care in Chicago Study. Alpana Kaushiva, University of Illinois at Chicago School of Public Health, Chicago, IL

B113 Colorectal cancer screening completion rates and barriers to colorectal cancer screening 6 months following participation to CRC screening intervention. Carolina López de la Torre, San Diego State University, San Diego, CA

B114 HCV Screening and Awareness Education Are Much Needed among African American Baby Boomers in Philadelphia. Grace Ma, Temple University, Philadelphia, PA
B115 Bridging the gap: Characterizing transportation barriers in rural southern Illinois. Julia Maki, Washington University School of Medicine, St. Louis, Missouri

B116 Cervical HPV testing with two home self-collected samples compared to clinically-collected samples. Jerry McLarty, LSU Haalth Sciences Center, Shreveport, LA

B117 Analysis of luminal breast cancer tumor microenvironment using seqFISH. Michal Polonsky, California Institute of Technology, Pasadena, CA

B118 Using A Multimodal Strategy to Engage Latino Communities and Improve Colorectal Cancer Screening Disparities. Sneha Prabhu, UT Health San Antonio, San Antonio, TX

B119 Receptiveness of metformin as a breast cancer prevention drug within the hispanic community. Mayra Serrano, City of Hope, Duarte, CA

B120 [Advocate Abstract:] Let’s create a generation of proactive consciousness. Fred Hardy, Karmanos Cancer Institute, MI

B121 Factors associated with HPV vaccination among childhood cancer survivors: Differences by Hispanic ethnicity and parental health literacy. Yazmin San Miguel, Moores Cancer Center and Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA

B122 Racial and ethnic disparities and reverse disparities in HPV vaccination: A meta-analysis. Jennifer Spencer, University of North Carolina at Chapel Hill, Chapel Hill, NC

B123 The genetic tone of prostate cancer risk linked to ancestry: Do we know all about genetic admixture, cancer, and ancestry? Oscar M. Vidal, Molecular Epidemiology Group-Universidad del Norte, Barranquilla, Colombia

B124 Indigenizing cancer bio-banks as a form of cultural resistance. Rodney C. Haring, Roswell Park Comprehensive Cancer Center, Buffalo, NY

B125 [Advocate Abstract:] Diane Nathaniel, Beat Stage 3, Inc.

B126 [Advocate Abstract:] W. Erika Nalls, Independent Advocate